IMGT/mAb-DB includes five mAbs targeting MS4A1 and two mAbs targeting CD19 for autoimmune diseases, of which four and one, respectively, have been approved by the FDA and/or EMA. This evidence concerns the gene CD19 and autoimmune disease.